CN1189365A - Medicine for preventing Aids virus, treponema pallidum, neisseria gonorrhoeae and trichomonad - Google Patents
Medicine for preventing Aids virus, treponema pallidum, neisseria gonorrhoeae and trichomonad Download PDFInfo
- Publication number
- CN1189365A CN1189365A CN97107951A CN97107951A CN1189365A CN 1189365 A CN1189365 A CN 1189365A CN 97107951 A CN97107951 A CN 97107951A CN 97107951 A CN97107951 A CN 97107951A CN 1189365 A CN1189365 A CN 1189365A
- Authority
- CN
- China
- Prior art keywords
- oil
- hiv
- treponema pallidum
- medicine
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
A medicine for deactivating AIDS virus (HIV) in body and preventing the infection of HIV, syphilitic spirochete, ganococcus and trichomoniasis by adding it to contraceptive film, condom, toilet soap, bath lotion and washing powder is prepared from natural plant through extracting active components and mixing with chemically synthetic medicine.
Description
The present invention relates to a medicine for resisting AIDS virus (HIV), treponema pallidum, gonococcus and trichomonad.
On 5 days 6.1981, 5 extraordinary and terrible cases, which occur continuously in a very short time, were reported by the disease control center, an authoritative health agency: 5 young male sex-lovers, all suffering from a very rare form of pneumonia, pneumocystis pneumonia, were not known to be physically strong and lost at least some of the immune competence, and reported that 2 of them died. On day 3, 7 months later, the facility reported that 26 young male sex-lovers suffered from a malignant tumor, and these 26 patients lost immune function, and reported that 8 people died. The patients who are concentrated in such a short time are eventually deprived of life. In the surprise, people are aware that people face a new incurable challenge. This was named "AIDS" (AIDS) after 5 years.
After 1981, HIV-infected individuals worldwide have doubled each year, and in some areas, even by several times, several tens of times. It quickly increased from about 10 million in the early 80 s to 2180 million in 1996. The number of spread countries and regions is also increased from one or two tomore than 200. It was calculated that 8500 new infectors should be added every day around the world. The world health organization predicts that in 2000, HIV-infected individuals will reach 4000-1 million people worldwide. AIDS is fierce in violence and high in fatality rate, and is called as 'century plague' and 'super cancer'. Causing serious harm to the society and the economy of all countries in the world.
The invention aims to provide a medicine for resisting HIV, treponema pallidum, gonococcus and trichomonad.
The medicine for resisting HIV, treponema pallidum, gonococcus and trichomonad provided by the invention comprises one or more of the following combinations: 0.1-2% of paeonol, 0.01-3% of camphor, 0.05-2% of clove oil, 0.1-3% of gossypol, 0.3-1% of cinnamaldehyde, 0.05-2.2% of fennel oil, 0.1-2% of catechol, 0.02-2.5% of eucalyptol, 0.6-3% of benzoic acid, 0.1-1.5% of liquiritin, 0.01-2.5% of musk, 0.01-3% of oleanolic acid, 0.01-2.1% of pepper oil, 0.1-2% of piperine, 0.01-2% of kumquat essential oil, 0.01-2% of garlicin, 0.001-2.5% of ginger oil, 0.01-2% of toad, 0.01-1.5% of peppermint oil, 0.01-5% of borneol, 0.01-3.5% of nitidine, 0.01-3.3% of arecoline, 0.01-2% of anise oil, 0.05-3% of ginnol, 0.01-2% of orange oil, 0.5% of theobromine, 0.5% of, 0.1-3% of theophylline, 0.1-1.2% of berberine, 0.1-5% of hop oil, 0.01-3.8% of anethole, 0.01-2% of bay oil, 0.1-2% of solanine, 0.01-3% of lycorine, 0.1-3% of rhododendron, 0.1-3% of grapefruit oil, 0.01-2% of civet, 0.02-4% of rosemary oil, 0.1-3% of perilla oil, 0.2-2% of bitter orange oil, 0.01-2.5% of rose oil, 0.01-2.8% of cardamom oil, 0.1-3% of thymol, 0.1-3% of magnolol, 0.1-3% of onion essential oil, 0.5-3% of baicalin, 0.1-3% of chrysophanol, 0.01-2% of emodin, 0.1-2% of ginsenoside, 0.01-1% of jatrorrhizine, 0.1-3% of kaempferol, 0.1-3% of naringin, 0.1-2% of rhein, 0.01-1% of thymol, 0.01-1% ofdeoxycholic acid, 0.03-1.5% of andrographis paniculata, 0.1-3% of houttuynin, 0.1-3% of isatin, 0.1-2% of sinapine, 0.01-1% of chlorogenic acid, 0.1-0.5% of alkannin, 0.1-1% of polygonin, 0.01-1% of benzalkonium bromide and 0.01-0.5% of chlorhexidine.
Before the solid medicine in the above-mentioned components is made into various medicines and health-care products, the above-mentioned solid medicine is ground into superfine powder which is passed through 200 meshes by adopting colloid mill so as to increase specific surface of medicine, and can make the medicine be easily absorbed in digestive tract, and can raise the medicine dissolving-out rate of health-care product, and can raise the capacity of sterilizing medicine and inactivating HIV so as to reduce the dosage of medicine.
The components of the medicine used in the invention are generally compounded to reduce the unpleasant smell and taste of the medicine and the irritation to skin mucosa. And prevent and interfere HIV, syphilis spiral from many aspectsBiological metabolism process of gonococcus, gonococcus and trichomonad: inhibiting virus replication and preventing HIV entry into T4The biosynthesis of DNA of lymphocyte, treponema pallidum, gonococcus and trichomonad, etc. can kill HIV and treponema pallidum, gonococcus and trichomonad quickly.
The medicines of the invention can be divided into six types of volatile oils, alkaloids, phenols, acids, animals and surfactants according to the characteristics of the physicochemical properties of the medicines. The preparation method comprises the following steps:
1. volatile oil type drugs: cinnamic aldehyde, eucalyptol, camphor, orange peel oil, anise aldehyde, clove oil, star anise oil, clove basil oil, fennel oil, cardamom oil, rose oil, citrus aurantium flower oil, perilla oil, rosemary oil, grapefruit oil, celery seed oil, menthol, pepper oil, anethole, borneol, bay oil, kumquat essential oil, onion essential oil, naringin, garlicin, ginger oil and hop oil. The preparation method comprises the following steps: crude drug → cut up → steam distillation → collection distillation
2. Alkaloid drugs: nitidine, jateorhizine, solanine, theobromine, arecoline, theophylline, lycopersine, berberine, zanthoxyline and piperine. The preparation method comprises the following steps: crude drug
3. Phenolic drugs: thymol, catechol, kaempferol, thymol, gossypol, chrysophanol, paeonol, and magnolol. The preparation method comprises the following steps: 
4. acid drugs: benzoic acid, benzoic acid,Rhein, cinnamic acid, oleanolic acid, deoxycholic acid, 
5. Animal drugs: zibethum, Moschus, and Bufo siccus. The preparation method comprises the following steps: directly taking off medicinal organs from medicinal animals, drying in the shade, and adding into medicine.
6. Surfactant-based drugs: benzalkonium bromide and chlorhexidine. The preparation method comprises the following steps:
a. preparation method of benzalkonium bromide 
b. Method for preparing chlorhexidine
Experiments show that the medicine of the present invention has complete inactivation and killing effect on HIV, treponema pallidum, gonococcus and trichomonad. HIV, treponema pallidum, gonococcus and trichomonad infection mainly comprises the following ways:
1. human sex with infected HIV, treponema pallidum, gonococcus and trichomonad;
2. injecting drugs, medicines and vaccines by using a needle or a needle tube polluted by HIV and treponema pallidum;
3. inputting plasma and blood products contaminated by HIV and treponema pallidum;
4. pregnant women infected with HIV and treponema pallidum have fertility;
5. HIV, syphilis helix, with the body fluids of the infected person (blood, semen, vaginal fluid, tears, saliva, urine, milk) pass through the damaged skin or mucous membrane in direct contact into another person.
In view of the transmission ways of HIV, treponema pallidum, diplococcus gonorrhoeae and trichomonad, one or more of the medicines for resisting HIV, treponema pallidum, diplococcus gonorrhoeae and trichomonad of the invention are prepared into medicines for resisting AIDS and venereal disease by oral administration, and one or more of the medicines are added into condoms, contraceptive membranes, soap, bath lotion and washing powder, thereby being a convenient method for preventing the transmission and infection of HIV, treponema pallidum, diplococcus gonorrhoeae, trichomonad and other venereal diseases in multiple ways for a long time.
Example 1:
anti-HIV contraceptive film
The first experiment method comprises the following steps: a contraceptive membrane containing2mg of nonylphenyl polyglycol ether, 1mg of paeonol, 2mg of glycyrrhizin, 1.5mg of polyvinyl alcohol, 1mg of glycerol, distilled water and the like is dissolved in 5ml of physiological saline and directly injected into an HIV-infected chicken embryo, and the inactivation of the liquid medicine on HIV is tested. The control group was treated with normal saline without drug as a parallel control.
II, experimental results:
1. HIV survived well in the control group.
2. HIV in the experimental group was completely inactivated within 2 minutes. Example 2:
anti-HIV perfumed soap
The first experiment method comprises the following steps: 0.2g of paeonol, 0.3g of liquiritin, 0.1g of cinnamaldehyde, a proper amount of soap base and a proper amount of essence, and 100g of the perfumed soap is prepared. 50mg of the suspension was dissolved in 5ml of physiological saline. The same procedure as in example 1 was followed.
II, experimental results:
1. HIV survived well in the control group.
2. HIV in the experimental group was completely inactivated within 1.5 minutes. Example 3:
anti-HIV condom
The first experiment method comprises the following steps: mixing gossypol 2mg, paeonol 2mg, benzoic acid 2mg and pulvis Talci 10mg, and sticking on the inner and outer membranes of condom. The inner and outer membranes were washed with 5ml of physiological saline and the drug solution was collected. The same procedure as in example 1 was followed.
II, experimental results:
1. HIV survived well in the control group.
2. HIV in the experimental group was completely inactivated within1 minute. Example 4:
anti-HIV shower gel
The first experiment method comprises the following steps: 0.1% of cinnamaldehyde, 0.2% of ginkgol, 0.1% of clove oil and 99.6g of a shower gel matrix are uniformly mixed, and 10mg of a finished product is dissolved in 5ml of physiological saline. The same procedure as in example 1 was followed.
II, experimental results:
1. HIV survived well in the control group.
2. HIV in the experimental group was completely inactivated within 1 minute. Example 5:
anti-HIV washing powder
The first experiment method comprises the following steps: 1g of menthol, 0.5g of anethole, 0.5g of chlorhexidine and 98g of washing powder substrate are taken to prepare 100g of washing powder. 5mg of the extract was dissolved in 5ml of physiological saline and treated in the same manner as in example 1.
II, experimental results:
1. HIV survived well in the control group.
2. HIV in the experimental group was completely inactivated within 2 minutes. Example 6:
anti-HIV contraceptive membrane, soap, condom, bath lotion, and washing powder can kill treponema pallidum, Diplococcus gonorrhoeae, and trichomonad.
The first experiment method comprises the following steps: the test solutions were prepared according to the methods of examples 1 to 6, and then added to the culture media of treponema pallidum, diplococcus gonorrhoeae, and trichomonad, respectively, to observe the killing effect. The control group was treated with normal saline without drug as a parallel control.
II, experimental results:
1. the control grouphad good survival of all treponema pallidum, Diplococcus gonorrhoeae and Trichomonas.
2. Treponema pallidum, Diplococcus gonorrhoeae and Trichomonas in the experimental group were completely killed within 1.5 min, 2 min and 2.5 min, respectively.
Claims (6)
1. The medicine for resisting AIDS virus (HIV), treponema pallidum, gonococcus and trichomonad is characterized in that the medicine contains one of the following components:
0.1-2% of paeonol, 0.01-3% of camphor, 0.05-2% of clove oil, 0.1-3% of gossypol, 0.3-1% of cinnamaldehyde, 0.05-2.2% of fennel oil, 0.1-2% of catechol, 0.02-2.5% of eucalyptol, 0.6-3% of benzoic acid, 0.1-1.5% of liquiritin, 0.01-2.5% of musk, 0.01-3% of oleanolic acid, 0.01-2.1% of pepper oil, 0.1-2% of piperine, 0.01-2% of kumquat essential oil, 0.01-2% of garlicin, 0.001-2.5% of ginger oil, 0.01-2% of toad, 0.01-1.5% of peppermint oil, 0.01-5% of borneol, 0.01-3.5% of nitidine, 0.01-3.3% of arecoline, 0.01-2% of anise oil, 0.05-3% of ginnol, 0.01-2% of orange oil, 0.5% of theobromine, 0.5% of, 0.1-3% of theophylline, 0.1-1.2% of berberine, 0.1-5% of hop oil, 0.01-3.8% of anethole, 0.01-2% of bay oil, 0.1-2% of solanine, 0.01-3% of solanine, 0.1-3% of rhododendron, 0.1-3% of grapefruit oil, 0.01-2% of civet, 0.02-4% of rosemary oil, 0.1-3% of perilla oil, 0.2-2% of bitter orange oil, 0.01-2.5% of rose oil, 0.01-2.8% of cardamom oil, 0.1-3% of thymol, 0.1-3% of magnolol, 0.1-3% of onion essential oil, 0.5-3% of baicalin, 0.1-3% of chrysophanol, 0.01-2% of emodin, 0.1-2% of ginsenoside, 0.01-1% of jatrorrhizine, 0.1-3% of kaempferol, 0.1-3% of naringin, 0.01-2% of rhein, 0.01-1% of thymol, 0.01-1% of deoxycholic acid, 0.03-1.5% of andrographis paniculata, 0.1-3% of houttuynin, 0.1-3% of isatin, 0.1-2% of sinapine, 0.01-1% of chlorogenic acid, 0.1-0.5% of alkannin, 0.1-1% of polygonin, 0.01-1% of benzalkonium bromide, 0.01-0.5% of chlorhexidine and the balance of auxiliary agents.
2. The anti-HIV, anti-treponema pallidum, anti-gonococcal and anti-trichomonas agent according to claim 1, wherein the agent comprises:
0.5% of paeonol, 0.1% of fennel oil, 1.5% of benzoic acid, 0.1% of oleanolic acid, 0.2% of piperine, 0.25% of nitidine, 0.1% of arecoline, 0.1% of theophylline, 0.3% of anethole, 0.5% of grapefruit oil, 1% of daidai oil, 1.5% of baicalin, 0.1% of emodin, 0.1% of kaempferol, 0.1% of deoxycholic acid, 2.5% of houttuynin and the balance of auxiliary agents.
3. The anti-HIV, anti-treponema pallidum, anti-gonococcal and anti-trichomonas agent according to claim 1, wherein the agent comprises:
0.1% clove oil, 2% musk, 0.05% allicin, 2% gingkgo alcohol, 3% orange peel oil, 0.05% bay oil, 1.5% civet, 1% rose oil, 2.2% cardamom oil, 2% chrysophanol, 0.5% naringin, 1% rhein, 0.4% woad glycoside, 0.1% sinapine, 0.2% alkannin, and the balance of auxiliary agents.
4. The anti-HIV, anti-treponema pallidum, anti-gonococcal and anti-trichomonas agent according to claim 1, wherein the agent comprises:
0.1% of camphor, 0.1% of catechol, 2.5% of gossypol, 1% of glycyrrhizin, 0.05% of kumquat essential oil, 1.5% of toad, 1% of peppermint oil, 1.5% of tomatidine, 2.5% of rhododendrin, 0.5% of perilla oil, 1% of ginsenoside, 0.5% of thymol, 0.5% of polydatin, 1% of chlorogenic acid, 1% of andrographis paniculata, 0.05% of benzalkonium bromide and the balance of auxiliary agents.
5. The anti-HIV, anti-treponema pallidum, anti-gonococcal and anti-trichomonas agent accordingto claim 1, wherein the agent comprises:
0.5% of cinnamaldehyde, 2% of eucalyptol, 1% of pepper oil, 1.5% of ginger oil, 4% of borneol, 1% of anise oil, 2% of theobromine, 1% of berberine, 2% of hop oil, 1% of solanine, 3% of rosemary oil, 1.5% of thymol, 0.2% of magnolol, 1% of onion, 0.5% of jatrorrhizine, 0.5% of chlorhexidine and the balance of auxiliary agents.
6. The anti-HIV, anti-treponema pallidum, anti-gonococcus, anti-trichomonas agent according to any one of claims 1 to 5 is prepared into any preparation and is added into contraceptive membranes, perfumed soaps, condoms, bath lotions and washing powders as an additive.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97107951A CN1189365A (en) | 1997-01-31 | 1997-01-31 | Medicine for preventing Aids virus, treponema pallidum, neisseria gonorrhoeae and trichomonad |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97107951A CN1189365A (en) | 1997-01-31 | 1997-01-31 | Medicine for preventing Aids virus, treponema pallidum, neisseria gonorrhoeae and trichomonad |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1189365A true CN1189365A (en) | 1998-08-05 |
Family
ID=5169991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN97107951A Pending CN1189365A (en) | 1997-01-31 | 1997-01-31 | Medicine for preventing Aids virus, treponema pallidum, neisseria gonorrhoeae and trichomonad |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1189365A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100427078C (en) * | 2005-11-22 | 2008-10-22 | 深圳海王药业有限公司 | Decanoyl acetaldehyde compound and its medicinal composition |
| US7674830B2 (en) | 2002-04-30 | 2010-03-09 | Unigen Pharmaceuticals, Inc. | Formulation of a mixture of free-B-ring flavonoids and flavans as a therapeutic agent |
| US8535735B2 (en) | 2002-03-01 | 2013-09-17 | Unigen, Inc. | Identification of free-B-ring flavonoids as potent COX-2 inhibitors |
| US8568799B2 (en) | 2002-03-22 | 2013-10-29 | Unigen, Inc. | Isolation of a dual COX-2 and 5-lipoxygenase inhibitor from acacia |
| CN103393799A (en) * | 2013-08-10 | 2013-11-20 | 蒋保珍 | Tradtional Chinese medicine composition for treating acquired immune deficiency syndrome and preparation method thereof |
| US8652535B2 (en) | 2002-04-30 | 2014-02-18 | Unigen, Inc. | Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments |
| US8790724B2 (en) | 2003-04-04 | 2014-07-29 | Unigen, Inc. | Formulation of dual cycloxygenase (COX) and lipoxygenase (LOX) inhibitors for mammal skin care |
| CN111700886A (en) * | 2020-04-23 | 2020-09-25 | 广州宏康医药科技有限公司 | Compound allicin soft capsule and preparation and packaging method thereof |
-
1997
- 1997-01-31 CN CN97107951A patent/CN1189365A/en active Pending
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8535735B2 (en) | 2002-03-01 | 2013-09-17 | Unigen, Inc. | Identification of free-B-ring flavonoids as potent COX-2 inhibitors |
| US9061039B2 (en) | 2002-03-01 | 2015-06-23 | Unigen, Inc. | Identification of Free-B-Ring flavonoids as potent COX-2 inhibitors |
| US9168242B2 (en) | 2002-03-22 | 2015-10-27 | Unigen, Inc. | Isolation of a dual COX-2 and 5-lipdxygenase inhibitor from Acacia |
| US8568799B2 (en) | 2002-03-22 | 2013-10-29 | Unigen, Inc. | Isolation of a dual COX-2 and 5-lipoxygenase inhibitor from acacia |
| US8652535B2 (en) | 2002-04-30 | 2014-02-18 | Unigen, Inc. | Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments |
| US7674830B2 (en) | 2002-04-30 | 2010-03-09 | Unigen Pharmaceuticals, Inc. | Formulation of a mixture of free-B-ring flavonoids and flavans as a therapeutic agent |
| US9370544B2 (en) | 2002-04-30 | 2016-06-21 | Unigen, Inc. | Formulation of a mixture of free-B-ring flavonoids and flavans as a therapeutic agent |
| US9655940B2 (en) | 2002-04-30 | 2017-05-23 | Unigen, Inc. | Formulation of a mixture of free-B-ring flavonoids and flavans as a therapeutic agent |
| US9849152B2 (en) | 2002-04-30 | 2017-12-26 | Unigen, Inc. | Formulation of a mixture of Free-B-ring flavonoids and flavans as a therapeutic agent |
| US8790724B2 (en) | 2003-04-04 | 2014-07-29 | Unigen, Inc. | Formulation of dual cycloxygenase (COX) and lipoxygenase (LOX) inhibitors for mammal skin care |
| US9622964B2 (en) | 2003-04-04 | 2017-04-18 | Unigen, Inc. | Formulation of dual cycloxygenase (COX) and lipoxygenase (LOX) inhibitors for mammal skin care |
| CN100427078C (en) * | 2005-11-22 | 2008-10-22 | 深圳海王药业有限公司 | Decanoyl acetaldehyde compound and its medicinal composition |
| CN103393799A (en) * | 2013-08-10 | 2013-11-20 | 蒋保珍 | Tradtional Chinese medicine composition for treating acquired immune deficiency syndrome and preparation method thereof |
| CN103393799B (en) * | 2013-08-10 | 2015-09-09 | 唐宏雁 | A kind of Chinese medicine composition for the treatment of acquired immune deficiency syndrome (AIDS) and preparation method thereof |
| CN111700886A (en) * | 2020-04-23 | 2020-09-25 | 广州宏康医药科技有限公司 | Compound allicin soft capsule and preparation and packaging method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| McKenna et al. | Black cohosh: efficacy, safety, and use in clinical and preclinical applications | |
| Talwar et al. | Plant immunomodulators for termination of unwanted pregnancy and for contraception and reproductive health | |
| JP2010527326A (en) | Trigonella foenum-glaecam extract | |
| CN113081928B (en) | Plant antibacterial gel and preparation method and application thereof | |
| CN103800772A (en) | Gynecological external lotion for preventing and treating vagina inflammatory diseases and preparation method thereof | |
| CN1189365A (en) | Medicine for preventing Aids virus, treponema pallidum, neisseria gonorrhoeae and trichomonad | |
| CN112043817A (en) | Anti-mite composition and application thereof | |
| CN1191130A (en) | Anti-AIDS virus, anti-Treponema pallidum, anti-gonococcus, anti-candida albicans and anti-trichomonas natural drug | |
| CN111419932A (en) | Composition with dual functions of bacteriostasis and nursing for male private parts and preparation method thereof | |
| US6428823B1 (en) | Biologically active aqueous fraction of an extract obtained from a mangrove plant Salvadora persica L | |
| US20170020946A1 (en) | Analgesic compositions and methods of use | |
| CN1970020B (en) | A pharmaceutical composition, preparation process and application thereof | |
| CN102349935A (en) | Purpose of ginkgolic acid in preparing external preparation for treating venereal disease, gynopathy and perianal disease | |
| JPH08133983A (en) | Extract of aspalathus linealis and its use | |
| CN1640873A (en) | Separation and extraction of flavone natural product active component for treating prostating disorders and medicinal preparation preparing and use thereof | |
| CN1308019C (en) | Chinese medicinal composition for treating chronic pelvic inflammation and preparation method thereof | |
| CN1431012A (en) | Externally used Chinese herbal medicine for treating gynecology inflammation | |
| CN111840399A (en) | Male private part nursing composition and preparation method thereof | |
| CN1943743A (en) | A medicine for treatment and prevention of vaginitis | |
| CN104189657B (en) | External contraceptive capable of preventing and curing genital tract infection | |
| WO2009088125A1 (en) | A composition for sanitary supplies comprising mucosal immunoadjuvant and a preparation method thereof | |
| CN1047206A (en) | The manufacture method that pruritus is clean | |
| CN107362310A (en) | It is a kind of to be used to repair Baicao Fuyanqing preparation of vagina environment and preparation method thereof | |
| CN104689121B (en) | A kind of preparation method for the treatment of the medicament of pruritus vulvae | |
| CN101020037A (en) | Wet sterilized towel used for couple's sexual life and its making process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C01 | Deemed withdrawal of patent application (patent law 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |